Century Therapeutics (IPSC) AI Stock Analysis

• Market Cap: $51.12M
• Dividend Yield: N/A
• Average Volume (3M): 462.31K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.46
• Revenue Growth: 7.92%
• EPS Growth: 15.15%
• Country: US
• Employees: 165
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -1.86
• Shares Outstanding: 85,029,045
• 10 Day Avg. Volume: 422,468
• 30 Day Avg. Volume: 462,309
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 19.27
• Price to Cash Flow (P/CF): -0.50
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $7.33
• Price Target Upside: 1121.67% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

Century Therapeutics is currently facing significant financial hurdles, with ongoing losses and negative cash flows being primary concerns. Technical indicators suggest a bearish outlook, compounded by an unattractive valuation due to negative earnings. However, recent corporate advancements in cell therapy technology provide a glimmer of potential improvement, offering a modestly positive outlook for future developments.

Positive Factors

Clinical Trial Progress

Century Therapeutics reported interim clinical data from the ongoing trial, showing an ORR of 83% and CR of 33% with participants receiving additional cycles.

Therapeutic Potential

The therapeutic potential and dosing flexibility of Century Therapeutics' Allo-Evasion technology promises superior clinical outcomes with CNTY-101 in autoimmune diseases.

Negative Factors

Partnership Termination

BMS' decision to discontinue their collaboration agreement with Century is disappointing and attributed to 'an internal corporate portfolio prioritization process.'

Century Therapeutics Business Overview & Revenue Model

Company Description

Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a significant unmet medical need. It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematological malignancies.

How the Company Makes Money

Century Therapeutics generates revenue primarily through strategic partnerships, collaborations, and licensing agreements with other biotechnology and pharmaceutical companies. These partnerships often involve upfront payments, milestone payments based on the achievement of specific development or regulatory goals, and royalties on future sales of successfully developed therapies. Additionally, Century Therapeutics may receive funding from grants and research contracts that support its product development efforts. The company's focus on advancing its pipeline of iPSC-derived cell therapies is a key factor contributing to its revenue potential, as successful commercialization of these therapies could lead to significant income from licensing and sales.

Century Therapeutics Financial Statement Overview

Summary

Century Therapeutics faces significant financial challenges with persistent losses and negative cash flows. Despite a decent equity buffer, the increasing leverage and inability to generate positive cash flow highlight risks in sustaining operations without external financing.

Income Statement

Century Therapeutics shows a consistent struggle with profitability, indicated by negative gross and net profit margins. The TTM data reveals a worsening EBIT and EBITDA margin, with revenue growth of 20.15%, yet it remains insufficient to cover high operational costs.

Balance Sheet

While Century Therapeutics maintains a relatively strong equity position, with a debt-to-equity ratio of 0.28, their declining equity ratio from 62.22% in 2022 to 50.34% TTM indicates rising leverage and potential financial strain.

Cash Flow

The company's cash flow situation is challenging, with negative operating and free cash flows, and a negative free cash flow growth rate. The operating cash flow to net income ratio remains below 1, indicating insufficient cash flow generation relative to losses.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
2.69M	2.23M	5.20M	0.00	0.00	0.00
	Gross Profit
-10.85M	-10.81M	-4.87M	-4.58M	-1.75M	-249.00K
	EBIT
-132.25M	-146.55M	-133.83M	-94.88M	-53.90M	-245.98M
	EBITDA
-117.21M	-121.21M	-119.34M	-89.92M	-51.44M	-19.78M
	Net Income Common Stockholders
-129.89M	-136.67M	-130.93M	-95.82M	-54.66M	-245.98M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
172.74M	172.74M	315.50M	222.88M	75.75M	81.54M
	Total Assets
360.69M	360.69M	486.54M	437.38M	106.78M	90.90M
	Total Debt
48.17M	48.17M	49.41M	23.46M	21.55M	0.00
	Net Debt
847.00K	847.00K	-34.85M	-32.98M	-5.66M	-44.06M
	Total Liabilities
175.94M	175.94M	183.81M	41.14M	213.19M	182.75M
	Stockholders Equity
184.75M	184.75M	302.74M	396.24M	-106.41M	-91.86M
Cash Flow		Free Cash Flow
-113.12M	-102.08M	-16.55M	-133.97M	-51.09M	-18.63M
	Operating Cash Flow
-112.14M	-88.35M	14.05M	-89.00M	-41.27M	-16.17M
	Investing Cash Flow
35.48M	61.13M	-13.13M	-298.34M	-22.76M	-19.83M
	Financing Cash Flow
74.81M	-9.72M	27.16M	417.77M	47.69M	74.84M

Century Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IPSC, the sentiment is Negative. The current price of 0.6 is below the 20-day moving average (MA) of 0.68, below the 50-day MA of 0.82, and below the 200-day MA of 1.62, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 29.16 is Positive, neither overbought nor oversold. The STOCH value of 26.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IPSC.

Century Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	49 Neutral	$6.90B	-0.08	-53.01%	2.43%	24.84%	-3.06%
CRSP	48 Neutral	$3.72B	―	-19.20%	―	-89.95%	-123.71%
IPSC	42 Neutral	$51.12M	―	-62.61%	―	7.92%	15.15%
BLUE	42 Neutral	$38.57M	―	-270.20%	―	144.50%	-141.91%
FATE	42 Neutral	$110.00M	―	-54.21%	―	-78.55%	-0.92%
EDIT	42 Neutral	$129.44M	―	-98.10%	―	-58.64%	-40.05%
NTLA	39 Underperform	$962.71M	―	-54.00%	―	59.55%	3.09%

Century Therapeutics Corporate Events

Century Therapeutics Unveils Advances in Cell Therapies

Century Therapeutics has released an updated corporate presentation detailing its progress in developing iPSC-derived cell therapies, including the lead product candidate CNTY-101, which targets B-cell malignancies and autoimmune diseases. The company highlights its advanced Allo-Evasion technology, which enhances immune evasion and allows repeat dosing without lymphodepletion, positioning Century as a leader in the field and potentially impacting its competitive standing in the biotechnology market.

Century Therapeutics Faces Termination of BMS Agreement

Century Therapeutics announced that Bristol-Myers Squibb will terminate their collaboration agreement effective March 12, 2025, following BMS’s internal portfolio prioritization. Despite this, Century remains optimistic about the scientific progress made and plans to explore opportunities in acute myeloid leukemia and multiple myeloma, aligning with their strategic review of the pre-clinical pipeline.